Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients
Freeman, Phillips M.
Moschonas, Konstantinos E.
O'Donnell, Valerie B.
Kinnaird, Tim D.
Anderson, Richard A.
MetadataShow full item record
Background High on treatment platelet reactivity (HTPR) is common in patients receiving clopidogrel following an acute coronary syndrome (ACS); it's also associated with increased morbidity and mortality. More potent and predictable antiplatelet drugs have addressed this issue at the expense of increased bleeding. Identification of HTPR and the targeted use of more potent antiplatelet drugs has, so far, broadly failed. We investigate this approach in terms of the timing of platelet function testing and how this can impact on the ability of these bedside tests to predict HTPR around the time of coronary intervention. Methods High risk ACS patients treated with 5 days of clopidogrel had platelet function assessed using the multiple electrode aggregometry system (MEA) pre, post and 24 h following percutaneous coronary intervention (PCI). Simultaneous detailed analysis of platelet status was undertaken with quantification of platelet bound and soluble p-selectin and mass spectrometry quantification of the eicosanoid 12-HETE. Results As assessed by MEA 40.5% of patients had HTPR pre-PCI; mean aggregation units (AU) in response to ADP were 499.1 ± 46.3 pre-PCI, 407.6 ± 37.7 post-PCI and 269.1 ± 24.6 AU 24 h post-PCI (pre to post PCI p > 0.05, pre to 24 h post-PCI p = 0.0002). This highly significant drop in platelet reactivity was contrasted with on-going expression of platelet bound p-selectin, increased soluble p-selectin and rising 12-HETE concentrations. Conclusions This study outlines significant changes in ex-vivo platelet aggregation that occur within 24 h of PCI in high risk NSTEMI patients using bedside PFT. Whilst there were no changes in antiplatelet therapy during the study period its clear that timing is crucial when assessing high on treatment residual platelet activity.
Freeman, P.M., Moschonas, K.E., Hinz, C., O'Donnell, V.B., Kinnaird, T.D., James, P.E. and Anderson, R.A. (2015) 'Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients', Atherosclerosis, 243(1), pp.320-327.
This article was published in Atherosclerosis on 18th September 2015 (online) available at http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.024 The Author's post-print is made available in this repository from 18th September 2016
Showing items related by title, author, subject and abstract.
Anderson, R.A.; Ellis, G.R.; Evans, L.M.; Morris, Keith; Chirkov, Y.Y.; Horowitz, J.D.; Jackson, S.K.; Rees, A.; Lewis, M.J.; Frenneaux, M.P. (MediNews (Diabetes) Ltd., 2005)Vascular responsiveness to exogenous nitrates in type 2 diabetes (T2DM) is attenuated in brachial and coronary vessels. We determined platelet responsiveness to nitric oxide (NO) in T2DM and control subjects. We examined ...
Dietary nitrate supplementation reduces circulating platelet-derived extracellular vesicles in coronary artery disease patients on clopidogrel therapy Burnley-Hall, Nicholas; Abdul, Fairoz; Androshu, Vitaliy; Morris, Keith; Ossei-Gerning, Nicholas; Anderson, Richard; Rees, D. Aled; James, Philip (Schattauer, 2018-01-05)Summary Extracellular vesicles (EVs) are implicated in the pathogenesis of cardiovascular disease (CVD). Specifically, platelet-derived EVs are highly pro-coagulant, promoting thrombin generation and fibrin clot formation. ...
Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention Bundhoo, Shantu; Sagan, Ewelina; James, Philip; Anderson, Richard (Thieme, 2017-11-27)Clopidogrel has been shown to have a morbidity and mortality benefit in the prevention of ischaemic complications in patients with acute coronary syndrome and/or after percutaneous coronary intervention (PCI)1. 600mg of ...